Business context and reporting period
This unaudited Form 10-Q is for the quarter and nine months ended September 30, 2015. The filing is for Trovagene, Inc., a molecular diagnostics company developing urine- and blood-based cell-free DNA tests, primarily for cancer monitoring—not Cardiff Oncology, Inc. Investors should verify the issuer and filing metadata.
Financial performance and liquidity
- Revenue: Third-quarter revenue was $57,327, essentially flat year over year; nine-month revenue was $233,643, up from $223,780. Revenue remained minimal and was principally royalties, with $10,712 of diagnostic service revenue for the nine months.
- Expenses and margins: Third-quarter operating expenses were $6.47 million and operating loss was $6.41 million. Nine-month operating expenses were $18.12 million and operating loss was $17.89 million. Diagnostic cost of revenue was $173,537 for the quarter and $429,992 for the nine months; management said diagnostic gross margins were negative as testing volume and operating efficiency remained insufficient to cover costs.
- Net loss: Net loss attributable to common shareholders was $2.74 million, or $0.10 basic loss per share, in the quarter, versus $5.38 million, or $0.28, a year earlier. For the nine months, the comparable loss was $20.11 million, or $0.80 per share, versus $9.66 million, or $0.51. The quarterly improvement included a $4.02 million non-cash gain from warrant fair-value changes; the nine-month period included a $1.11 million loss on that measure.
- Cash flow: Operating cash use was $15.31 million for the nine months, compared with $8.86 million in 2014; investing cash use was $1.26 million, mainly for capital equipment. Financing provided $63.42 million, principally from equity issuance. Cash and cash equivalents were $74.15 million at September 30, 2015.
- Liquidity and debt: Working capital was $67.85 million, versus $23.23 million at December 31, 2014. Debt carrying amounts were $3.75 million current and $11.52 million long-term. The loan’s interest-only period was extended through February 1, 2016, when principal and interest payments were scheduled to begin; the company reported covenant compliance.
- Equity: Common shares outstanding increased to 29.72 million from 18.92 million at year-end 2014. The company reported $61.22 million of net proceeds from common-stock sales during the nine months.
Changes, outlook, and risks
- Compared with 2014, nine-month operating costs rose substantially: research and development increased $2.60 million, selling and marketing $2.81 million, and general and administrative $1.62 million. Management attributed increases to more clinical collaborations, expanded staffing and commercial activity, and related support costs.
- Management expects operating cash outflows for the next several years and anticipates continued increases in research and development, selling and marketing, and general and administrative expenses. It expects diagnostic service revenue to increase, but timing is uncertain because service revenue is recognized on cash collection; no quantified earnings or revenue guidance was provided.
- The company described early-stage commercialization and substantial uncertainty around clinical validation, regulatory requirements, reimbursement, market adoption, competition, and access to future capital. Insufficient reimbursement or additional funding could constrain commercialization and may require delaying or reducing programs.
- A potentially material federal and state tax exposure related to certain executive compensation was identified; no liability was accrued, and the filing does not provide a clear estimated amount. The company also disclosed a possible CEO bonus of approximately $3.5 million if specified share-price and trading-volume conditions are met, and an expanded laboratory lease expected to raise monthly rent from approximately $30,000 to $60,000 when the new space is occupied, expected in early 2016.
- Management reported effective disclosure controls as of September 30, 2015 and no material change in internal control over financial reporting during the quarter. No material pending legal proceedings were reported.
Most important facts to verify
- Confirm that this Trovagene filing, rather than a Cardiff Oncology filing, is the intended document.
- Assess cash runway against the reported operating cash use and expected continued outflows, including the start of principal payments in February 2016.
- Evaluate whether clinical results translate into validated tests, reimbursement, and recurring commercial revenue.
- Investigate the potential executive-compensation tax exposure, which was unaccrued and not quantified clearly.
- Review dilution from equity issuance and outstanding options and warrants, as well as warrant fair-value effects on reported earnings per share.